Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Daily doxycycline hyclate 100mg Clear all

Conditions: Cystic Fibrosis
Interventions: Doxycycline, No doxycycline; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Blepharitis
Interventions: doxycycline, azithromycin; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy Volunteers, Fungal Infections, Bacterial Infections
Interventions: Doxycycline, Voriconazole; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 8 Years to 100 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CoVid 19 Positive
Interventions: Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum; Drug
Lead sponsor: The Camelot Foundation; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer, Skin Toxicities
Interventions: Minocycline, Hypochlorous Acid, Hydrocortison cream, Triamcinolone (TAC) 0.1% cream, Clobetasol, Photoprotection, Ivermectin; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid); Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Urethritis
Interventions: Azithromycin, Doxycycline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 16 Years and older · Male only
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sinusitis
Interventions: Doxycycline, Azithromycin, Augmentin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gonorrhea, Chlamydia, Syphilis
Interventions: On demand doxycycline hyclate 200mg, Daily doxycycline hyclate 100mg, Weekly doxycycline hyclate 100mg; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Arthritis, Reactive, Reiter Disease
Interventions: Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Tampa, Florida • New Orleans, Louisiana

Conditions: Mycoplasma Genitalium Infection
Interventions: Lefamulin, Doxycycline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Syphilis
Interventions: Doxycycline 200mg daily for 14 days; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Amyloidosis
Interventions: Doxycycline 100 mg po bid x 12 months; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions: Doxycycline or Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Systemic Amyloidosis
Interventions: Doxycycline; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Acne Vulgaris
Interventions: Sarecycline, Doxycycline; Drug
Lead sponsor: Integrative Skin Science and Research; Industry
Eligibility: 9 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Sexually Transmitted Infection
Interventions: Doxycycline; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rosacea
Interventions: Doxycycline, Ivermectin Topical; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acne Vulgaris
Interventions: Doxycycline 100mg, Aczone 5% gel; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Type 2 Diabetes, Obesity
Interventions: Doxycycline, Placebo; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bacterial Corneal Ulcer
Interventions: ProProKera Plus®; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Emphysema, HIV
Interventions: Doxycycline, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 30 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Sexually Transmitted Infection
Interventions: Single-Dose PK Phase - DR Group, Single-Dose PK Phase - IR Group, Multi-Dose PK Phase - Daily Group, Multi-Dose PK Phase - Intermittent Group; Drug
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Doxycycline Effects on Inflammation in Cystic Fibrosis

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

Lipids of the Human Tear Film and Their Effect on Tear Stability

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

Daily, Weekly, or Event-driven Doxycycline for STI Prevention Among Men Who Have Sex With Men (MSM) Engaging in Chemsex: The DOSE Non-inferiority Trial

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Lefamulin for M. Genitalium Treatment Failures

Daily Doxycycline for Early Syphillis

Safety and Effect of Doxycycline in Patients With Amyloidosis

Influence of MMP on Brain AVM Hemorrhage

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

Analysis of the Microbiome in Rosacea

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

Characterization of Doxycycline Pharmacokinetics and Adherence